Article

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men

Institute of Cancer Research, Sutton, Surrey, UK.
Scientific Reports (Impact Factor: 5.08). 06/2013; 3:2059. DOI: 10.1038/srep02059
Source: PubMed

ABSTRACT Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413 BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7% and specificity of 89.3% for cancer detection. There was no statistically significant difference in EN2 levels according to genetic status or Gleason score. Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals.

1 Bookmark
 · 
130 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Extensive efforts to identify a clinically useful biomarker for the diagnosis of prostate cancer have resulted in important insights into the biology of the disease, but no new test has been approved by regulatory authorities. The unmet need has also shifted to identifying biomarkers that not only diagnose prostate cancer but also indicate whether the patient has 'significant' disease. EN2 is a homeobox-containing transcription factor secreted specifically by prostate cancers into urine, where it can be detected by a simple ELISA assay. A number of studies have demonstrated the enormous potential of EN2 to address this unmet need and provide the urologist with a simple, cheap and efficient prostate cancer biomarker.
    Biomarkers in Medicine 12/2013; 7(6):893-901. DOI:10.2217/bmm.13.115 · 3.22 Impact Factor

Full-text (3 Sources)

Download
35 Downloads
Available from
May 16, 2014